An Intervention Study for Adults with Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors

This study is currently closed to enrollment.

Proof-of-Activity Study with Orticumab in Subjects with Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors

AGE: 30 years and older
SEX AT BIRTH: All

TYPE: Interventional Drug Study
CONDITION: Plaque psoriasis

HEALTHY PARTICIPANTS: No
LOCATION: University Hospitals Cleveland Medical Center

Study Purpose

The purpose of this research study is to test an experimental drug called Orticumab, a monocolonal antibody, to assess the safety and tolerability in subjects with moderate-to-severe psoriasis and cardiometabolic risk factors (obesity, high low-density lipoprotein (also called “LDL” or “bad” cholesterol), high blood fat (triglycerides), low high-density lipoprotein (also called “HDL” or “good” cholesterol), high blood pressure, diabetes, smoking tobacco).

STUDY ID#

STUDY20210910